Blog

🚀 Fantastic news!! We couldn't be more proud and excited to have recently closed our €3.6M financing round led by LUMO Labs, an impact-driven Dutch VC firm. With this financing, we will unlock product-market-fit of our clinical-grade AI software for blood cancer and other blood tests from cytometry. We aim to make your blood speak.

‍

A big shoutout to our committed investors Elaia and especially Clément Vanden Driessche, Heal Capital and Christian Lautner, HTGF | High-Tech Gründerfonds and Dr. Nik Raupp, the visionary laboratory who also re-invested again Labor Becker MVZ eGbR and especially Marc Becker and Malte von Trotha and our angel investors and especially Thomas Henkel. This wouldn't have been possible without your continued support over the past three years.We're also very thankful to our other new investors Bayern Kapital and especially Matthias Buchinger, the US angels Cross Atlantic Angels and especially Jens Weitzel and Niklas Herriger, and Akwa Group but especially Pim Hollestelle and Thomas Hannes our lead investor LUMO Labs for all believing in our bold vision to get every patient an accurate diagnosis as early as possible.

‍

This round motivates us to push even harder to build innovative technology in cytometry to save many patients' lives and find the best possible treatment for everyone's unique immune system.

‍

‍

Our cutting-edge AI model combines supervised and clustering approaches to detect small pathological B-cell populations in blood and bone marrow samples. Key features include:

• Efficient identification of populations as small as 3% of total cells
• Differentiation of 6 B-cell neoplasms (CLL, MCL, HCL, FL, MZL, DLBCL)
• Ability to detect previously unnoticed secondary B-NHL clones
• Optimized for low false negative rate, enabling fast and automated screening

This AI-powered tool offers systematic, rapid analysis, making it an invaluable aid for clinical B-cell neoplasm flow cytometry analysis in your laboratory. You can download the poster here.

End of May, we closed our seed round with Elaia Partners, heal capital and HTGF to bring precision diagnostics to immune medicine. Anne-Sophie Carrese says, about the deal: "We have been convinced by the founding team, composed of three former entrepreneurs from the same company, with three PhD profiles, at a stage where they are going to scale their go to market, which is coherent with our deep tech seed investment thesis", Managing Partner at Elaia Partners. See tech.eu's press release here.

.. we've achieved FDA-compliance (as a class I device) less than four months after receiving our CE mark. This was made possible by the professionalism and dedication of our team, but in particular by our US regulatory partner QServe Group, and our contact Jennifer Hadfield (left in picture), and our EU regulatory partner Be-on-Quality. The picture shows Aleks and Jennifer registering our device; the following day the FDA sent us the good news.

We're incredibly proud to share that hema.to has been clinically validated in an international, four-center clinical study! Blood cancer diagnoses were made twice as fast and at clinical-grade when made with the help of our beautiful, easy-to-use decision-support software. You can download the press release here.

... at the Medical Innovation Night in Nürnberg, where we pitched hema.to in front of an audience an an excellent jury consisting of Medical Valley EMN e. V., Siemens Healthineers, aescuvest, GWQ ServicePlus AG, IONOS andFraunhofer IIS. We'll be using our E20k prize money to explore partnerships with GWQ and Siemens Healthineers.

... we are now compliant with the IVDD. We conform to ISO 13485 (quality management), ISO 14971 (risk management), ISO 62366 (usability), ISO 62304 (software life-cycle management) and IEC 82304 (health software).